SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August: 2024 Wedbush PacGrow Healthcare Conference Tuesday, August 13, 2024, at 2:30 p.m. ET Canaccord Genuity 44th Annual Growth Conference Wednesday, August 14, 2024, at 12:30 p.m. ET A live webcast of the Canaccord Genuity 44th Annual Growth Conference presentation will be accessible on the Investor page of Travere's ...

SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August: 2024 Wedbush PacGrow Healthcare Conference Tuesday, August 13, 2024, at 2:30 p.m. ET Canaccord Genuity 44th Annual Growth Conference Wednesday, August 14, 2024, at 12:30 p.m. ET A live webcast of the Canaccord Genuity 44th Annual Growth Conference presentation will be accessible on the Investor page of Travere's ...

For the quarter ended June 2024, Travere Therapeutics (TVTX) reported revenue of $54.12 million, down 9.4% over the same period last year. EPS came in at -$0.90, compared to -$1.13 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $49.5 million, representing a surprise of +9.33%. The company delivered an EPS surprise of -3.45%, with the consensus EPS estimate being -$0.87. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings ...

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $1.13 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -3.45%. A quarter ago, it was expected that this drug developer would post a loss of $0.98 per share when it actually produced a loss of $1.76, delivering a surprise of -79.59%. Over the last four quarters, the compa ...

Received 521 new patient start forms (PSFs) for FILSPARI® (sparsentan) in the quarter representing the sixth consecutive quarter of PSF growth; Total of 2,484 PSFs received since launch Net product sales of FILSPARI totaled $27.1 million for the second quarter of 2024 representing 37% growth over the previous quarter Company well-positioned for September 5, 2024 PDUFA target action date for conversion of the U.S. accelerated approval of FILSPARI to full approval in IgAN Total revenue for the second quarter ...

SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced it will report second quarter 2024 financial results on Thursday, August 1, 2024, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Follo ...

Company Overview - Travere Therapeutics (TVTX) shares increased by 8.8% to $9.49 in the last trading session, with a notable trading volume, and have gained 19.9% over the past four weeks [2][3] - The company markets Filspari (sparsentan), approved for treating IgA nephropathy, which has generated $40 million in sales in Q1 2024, indicating strong market uptake [3] Financial Performance - The upcoming quarterly report is expected to show a loss of $0.87 per share, reflecting a year-over-year increase of 23%, while revenues are projected to be $49.5 million, down 17.1% from the previous year [4] - The consensus EPS estimate for Travere has remained unchanged over the last 30 days, suggesting that stock price movements may be limited without earnings estimate revisions [1][6] Industry Context - Travere is part of the Zacks Medical - Biomedical and Genetics industry, which includes other companies like Entrada Therapeutics, Inc. (TRDA), that saw a 2.7% increase in its last trading session [5] - Entrada Therapeutics has a consensus EPS estimate of $0.65, reflecting a 183.3% year-over-year change, and currently holds a Zacks Rank of 1 (Strong Buy) [7]

About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse ...

A live webcast will be accessible on the Investor page of Travere's website at ir.travere.com/eventspresentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024, at 11:30 a.m. ET. At Travere Therapeutics, we are in rare for life. We ar ...

The sudden rise in the stock price has likely been driven by the growing optimism of investors regarding Filspari's (sparsentan) potential to earn increasing revenues for the company. The drug, approved for treating IgA nephropathy, a form of kidney disease, has been witnessing solid uptake in the market. Travere recorded sales of $40 million in first-quarter 2024, up 65% year-over-year, primarily driven by an increase in sales from the ongoing commercial launch of Filspari. The company is also looking to e ...